
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.
The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.
Disclosure information is available at the beginning of the video presentation.
4.5
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.
The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.
Disclosure information is available at the beginning of the video presentation.
811 Listeners
5 Listeners
17 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
27 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
3,872 Listeners
38 Listeners
2 Listeners
113 Listeners
786 Listeners
10 Listeners
2 Listeners
58 Listeners
21 Listeners
169 Listeners
39 Listeners